Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell CAR Tin Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Next Previous
Trial Profile

Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell CAR Tin Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zevorcabtagene autoleucel (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms LUMMICAR 1
  • Sponsors CARsgen

Most Recent Events

  • 06 Mar 2026 According to a CARsgen media release, the updated long-term follow-up results of Phase I clinical trial of CT053 have been published in Blood Advances.
  • 10 Dec 2024 Results(Between December 1 2020, and March 2 2022 , n=102) assessing the potential impact of patient characteristics on the clinical efficacy of zevorcel in RRMM through subgroup analyses , presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 01 Mar 2024 According to a CARsgen media release, the National Medical Products Administration ("NMPA") of China has approved the New Drug Application ("NDA") for zevorcabtagene autoleucel, for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent), based on results form this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top